Real-world evidence supports CAR-T-cell therapy’s safety and efficacy

• A retrospective study in 275 (treated) patients with relapsed or refractory large B-cell lymphoma found (Yescarta) axicabtagene ciloleucel gave similar responses to those seen in clinical trials
• This evidence is valuable in supporting the clinical trial results; because “The issue with clinical trials is that they often are very highly selective,” – Michael D. Jain, MD, PhD; Moffitt Cancer Center
• “Our work is important because it shows that even those patients who don’t strictly adhere to clinical trial inclusion and exclusion criteria can still benefit from this therapy,” – Michael D. Jain
• These real-world results should give clinicians confidence with prescribing the CAR-T, especially for patients who do not fall under the clinical trial criteria

Click here to learn more

About SVMPharma

SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.

For more information, please visit www.svmpharma.com and contact us at enquiry@svmpharma.com

ref: AUG2020LN001